Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 62

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 62

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 62

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 79

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 79

Warning: date(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /var/www/vhosts/biocom.org/httpdocs/_modules/template_classes/_classes/PressRelease.php on line 79
BIOCOM ::

Deals and Data

Drugs from Amgen Inc and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident. (Reuters, 05/01/13)

Scripps Clinic
and Cytori Therapeutics begin clinical trial of a stem cell therapy to treat for heart failure and coronary artery disease. (U-T San Diego, 05/01/13)

Abide
signs drug development deal with Merck to develop three drugs for type 2 diabetes and other metabolic diseases. (U-T San Diego, 05/02/13)

Merck & Co.
won U.S. marketing approval for Liptruzet, a combination of the company’s Zetia pill and a generic version of Pfizer Inc.’s Lipitor, to lower elevated levels of bad cholesterol. (Bloomberg, 05/03/13)

Bristol-Myers Squibb
will use Ambrx’s protein medicinal technology to develop antibody drug conjugates for unspecified cancer indications. (GENNews, 05/03/13)

A study from The Scripps Research Institute shows their heroin-blocking vaccine has proven its effectiveness in rats and is ready for human clinical trials. (U-T San Diego, 05/06/13)

Celgene
to work with Concert Pharmaceuticals’ deuterated chemical entity (DCE) Platform technology to create new deuterium-modified small molecule compounds targeting cancer and inflammation. (GENNews, 05/06/13)

FDA approves Bristol-Myers Squibb’s Sustiva (efavirenz) for HIV-1 in pediatric patients as young as 3 months and weighing at least 7.7 pounds. (DSN, 05/06/13)

ResMed
continues to grow as it extends its breathing device product line, including products to help with chronic obstructive pulmonary disease. (U-T San Diego, 05/07/13)

Belviq, Arena Pharmaceuticals' weight-loss drug, receives last regulatory approval necessary to begin sales and will be Arena's first product on the market. (U-T San Diego, 05/07/13)

Shire
and Nimbus Discovery enter co-development agreement focused on small molecule treatments for lysosomal storage disorders with the hope to reach previously inaccessible tissues. (GENNews, 05/08/13)

FDA accepts Merck & Co.’s biologics license application for a dissolvable tablet to treat ragweed pollen allergies and expects the agency to complete its review in the first half of 2014. (Fox Business, 05/08/13)

Lumena Pharmaceuticals
, a startup developer of drugs for rare liver diseases, raises $23 million that will primarily go toward testing LUM001, which blocks reabsorption of bile from the small intestine into the blood, allowing it to be excreted. (U-T San Diego, 05/08/13)

TSRI
’s scientists discover how to inhibit or promote a natural gene-silencing mechanism that uses regulatory molecules called microRNAs to help Argonaute2 find RNA made from genes and destroy them. (U-T San Diego, 05/09/13)

FDA approves NovatisIlaris to treat serious form of childhood arthritis; the drug is the only approved treatment specifically for the condition that can be given as a monthly subcutaneous injection. (Reuters, 05/10/13)

Amgen
and Zhejiang Beta Pharma will form a joint venture to commercialize Amgen’s metastatic colorectal cancer drug (mCRC) Vectibix (panitumumab) in China. (GENNews, 05/10/13)

FDA approves Glaxo/Theravance drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. (Reuters, 05/10/13)

Merck & Co.
, Bristol-Myers Squibb Co. and Roche Holding AG open new front against cancer with next generation of experimental drugs that use the human immune system to seek and destroy tumor cells; seen extending lives. (Bloomberg, 05/12/13)

Life Technologies
launches sublicensing program for technology covering nucleic acids encoding Transcription Activator-Like Effector Nuclease fusion proteins,or TALENS, one month after a patent for the technology was issued. (GenomeWeb Daily News, 05/13/13)

Federal regulators grant priority review for Janssen Research & Development’s experimental treatment for hepatitis C, a contagious liver disease that affects more than 3 million people in the United States. (NJ.Com, 05/13/13)

Salk Institute
researchers may have found a drug that can not just stop but reverse symptoms of Alzheimer’s disease. (U-T San Diego, 05/13/13)

Research team including Sanford-Burnham Medical Research Institute and UCSD scientists is awarded $6 million to develop nanotechnology treatments for traumatic brain injuries and related infections. (U-T San Diego, 05/13/13)

Sorrento Therapeutics
and Igdrasol secure exclusive E.U. distribution rights to cancer drug, Cynviloq for metastatic breast cancer, non-small-cell lung cancer, and ovarian cancer. (GENNews, 05/14/13)

Sanofi
recruits patients for two new trials for their arthritis treatment, sarilumab, to treat moderate-to-severe rheumatoid polyarthritis. (Yahoo! News, 05/14/13)

Genentech nails new and patented version of Rituxan, which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. (Xconomy, 05/15/13)

« Return to Table of Contents